BRAF and neoplasm: Most of the genomic abnormalities were of the BRAFV600E mutations, but other BRAF mutations included not evaluable (NE) in cases with G466A and N486_P490del and progressive disease (PD) in cases with V600R. Durable partial response (PR) were observed in various tumour types (Fig. 3).